Recent developments in research
- LCRF adds $3.75 million in research funding opportunities
- ADC for EGFR+ lung cancer gets accelerated approval
- New treatment for ROS1+ non-small cell lung cancer
- LCRF announces grant focused on curing EGFR+ lung cancers
- LCRF announces new research collaboration with Boehringer Ingelheim
- Accelerated approval for c-MET directed ADC
- 1-year updates from research grantees
- LCRF-funded work highlighted at AACR annual meeting
- Science Update | Spring 2025
Recent FDA approvals
- Accelerated approval for c-MET directed ADC
- New FDA approval for EGFR exon 19 and exon 21 L858R
- FDA approves alectinib for ALK+ NSCLC
- Recent FDA approval of combined therapy for initial treatment of EGFR-mutated NSCLC
- FDA approves repotrectinib for patients with advanced ROS-1 fusion non-small cell lung cancer
- FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC
